
Opinion|Videos|February 1, 2025
One Institution’s Evidence-Based Approach to Adopting Biosimilars
A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process that examines clinical data, safety profiles, and cost implications while prioritizing operational efficiency, patient access, and seamless transitions between reference products and biosimilars.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Please describe the process your institution uses to review biosimilars as potential additions to the formulary.
- What priorities were identified by your institution for the purposes of operationalizing the use of biosimilars?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
2
FDA approves first treatment for chronic hepatitis D virus
3
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
4
Family healthcare costs reach $37,824, analysis finds
5





















